{"id":3179,"date":"2017-06-15T15:12:47","date_gmt":"2017-06-15T14:12:47","guid":{"rendered":"https:\/\/blogs.bmj.com\/medical-ethics\/?p=3179"},"modified":"2017-06-15T21:28:00","modified_gmt":"2017-06-15T20:28:00","slug":"nows-interest-in-pharmaceutical-gender-equity-seems-to-have-disappeared-with-its-funding","status":"publish","type":"post","link":"https:\/\/blogs.bmj.com\/medical-ethics\/2017\/06\/15\/nows-interest-in-pharmaceutical-gender-equity-seems-to-have-disappeared-with-its-funding\/","title":{"rendered":"&#8220;NOW\u2019s interest in pharmaceutical gender equity seems to have disappeared with its funding.&#8221;"},"content":{"rendered":"<p>There&#8217;s a <span style=\"color: #0000ff\"><a style=\"color: #0000ff\" href=\"http:\/\/www.thehastingscenter.org\/the-score-is-even\/\" target=\"_blank\" rel=\"noopener noreferrer\">remarkable piece<\/a><\/span> on the Hastings Center&#8217;s blog by Alycia Hogenmiller about a drug called Addyi. \u00a0Addyi is a drug that doesn&#8217;t work to treat a condition that doesn&#8217;t exist, pushed by campaigners who are actually industry shills.<\/p>\n<blockquote><p>Sprout Pharmaceuticals, run by Cindy and Robert Whitehead, was determined to obtain regulatory approval for flibanserin (Addyi), an antidepressant-turned-aphrodisiac that had already twice failed to gain approval by the FDA. \u00a0To create this fake feminist campaign, Sprout hired Blue Engine Media, a PR firm that created a sham organization called Even the Score. The campaign hired two feminists: a former director of the FDA Office of Women\u2019s Health, and the former president of the Women\u2019s Research and Education Institute \u2013 both well-known to women\u2019s groups. \u00a0Even the Score recruited and paid consumer advocacy groups to pressure the FDA into approving flibanserin for Hypoactive Sexual Desire Disorder \u2013 a condition previously created by industry to sell another drug.<\/p><\/blockquote>\n<p>I want to know more about those people hired. \u00a0What were they thinking? \u00a0What did they think they were doing? \u00a0What\u00a0<em>weren&#8217;t<\/em> they thinking?<\/p>\n<blockquote><p>It\u2019s sad to see advocacy groups become mouthpieces for pharma. \u00a0It is even sadder when those mouthpieces are feminist groups that should be protecting the interest of women but instead are protecting a company\u2019s bottom line. \u00a0Every single one of the advocacy groups that don\u2019t take money from pharmaceutical companies opposed Addyi\u2019s approval and use. \u00a0For example, the National Women\u2019s Health Network, the Jacobs Institute for Women\u2019s Health, the National Center for Health Research, the Reproductive Health Technologies Project, and the New View campaign all publicly opposed the drug before and after approval. \u00a0\u201cThis decision to approve flibanserin is a triumph of marketing over science,\u201d\u00a0said Cindy Pearson, head of the National Women\u2019s Health Network.<\/p>\n<p>[&#8230;]<\/p>\n<p>Addyi was never a true symbol for gender equity. \u00a0The drug doesn\u2019t work well and was never safe.<\/p><\/blockquote>\n<p>Just roll back a bit&#8230;<\/p>\n<blockquote><p>Every single one of the advocacy groups that don\u2019t take money from pharmaceutical companies opposed Addyi\u2019s approval and use.<\/p><\/blockquote>\n<p>Whoa.<\/p>\n<blockquote><p>Several lessons can be learned from the story of Even the Score. \u00a0First, don\u2019t trust, support, or listen to purported consumer advocacy groups that take money from pharmaceutical companies.<\/p><\/blockquote>\n<p>D&#8217;ya reckon?<\/p>\n<p>Go and read the whole thing. \u00a0It&#8217;s astonishing.<\/p>\n<p>The conference in respect of which the post is written <span style=\"color: #0000ff\"><a style=\"color: #0000ff\" href=\"http:\/\/www.pharmedout.org\/2017-conference.html\" target=\"_blank\" rel=\"noopener noreferrer\">looks good<\/a><\/span>, too.<!--TrendMD v2.4.8--><\/p>\n","protected":false},"excerpt":{"rendered":"<p>There&#8217;s a remarkable piece on the Hastings Center&#8217;s blog by Alycia Hogenmiller about a drug called Addyi. \u00a0Addyi is a drug that doesn&#8217;t work to treat a condition that doesn&#8217;t exist, pushed by campaigners who are actually industry shills. Sprout Pharmaceuticals, run by Cindy and Robert Whitehead, was determined to obtain regulatory approval for flibanserin [&#8230;]<\/p>\n<p><a class=\"btn btn-secondary understrap-read-more-link\" href=\"https:\/\/blogs.bmj.com\/medical-ethics\/2017\/06\/15\/nows-interest-in-pharmaceutical-gender-equity-seems-to-have-disappeared-with-its-funding\/\">Read More&#8230;<\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1240,185,7988,397,407],"tags":[304,317],"class_list":["post-3179","post","type-post","status-publish","format-standard","hentry","category-blogosphere","category-conferences","category-regulation-and-regulators","category-research-ethics","category-wtf","tag-public-health","tag-research"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.5 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>&quot;NOW\u2019s interest in pharmaceutical gender equity seems to have disappeared with its funding.&quot; - Journal of Medical Ethics blog<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/blogs.bmj.com\/medical-ethics\/2017\/06\/15\/nows-interest-in-pharmaceutical-gender-equity-seems-to-have-disappeared-with-its-funding\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"&quot;NOW\u2019s interest in pharmaceutical gender equity seems to have disappeared with its funding.&quot; - Journal of Medical Ethics blog\" \/>\n<meta property=\"og:description\" content=\"There&#8217;s a remarkable piece on the Hastings Center&#8217;s blog by Alycia Hogenmiller about a drug called Addyi. \u00a0Addyi is a drug that doesn&#8217;t work to treat a condition that doesn&#8217;t exist, pushed by campaigners who are actually industry shills. Sprout Pharmaceuticals, run by Cindy and Robert Whitehead, was determined to obtain regulatory approval for flibanserin [...]Read More...\" \/>\n<meta property=\"og:url\" content=\"https:\/\/blogs.bmj.com\/medical-ethics\/2017\/06\/15\/nows-interest-in-pharmaceutical-gender-equity-seems-to-have-disappeared-with-its-funding\/\" \/>\n<meta property=\"og:site_name\" content=\"Journal of Medical Ethics blog\" \/>\n<meta property=\"article:published_time\" content=\"2017-06-15T14:12:47+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2017-06-15T20:28:00+00:00\" \/>\n<meta name=\"author\" content=\"BMJ\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"BMJ\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/blogs.bmj.com\\\/medical-ethics\\\/2017\\\/06\\\/15\\\/nows-interest-in-pharmaceutical-gender-equity-seems-to-have-disappeared-with-its-funding\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/blogs.bmj.com\\\/medical-ethics\\\/2017\\\/06\\\/15\\\/nows-interest-in-pharmaceutical-gender-equity-seems-to-have-disappeared-with-its-funding\\\/\"},\"author\":{\"name\":\"BMJ\",\"@id\":\"https:\\\/\\\/blogs.bmj.com\\\/medical-ethics\\\/#\\\/schema\\\/person\\\/ba3da426ed20e8f1d933ca367d8216fe\"},\"headline\":\"&#8220;NOW\u2019s interest in pharmaceutical gender equity seems to have disappeared with its funding.&#8221;\",\"datePublished\":\"2017-06-15T14:12:47+00:00\",\"dateModified\":\"2017-06-15T20:28:00+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/blogs.bmj.com\\\/medical-ethics\\\/2017\\\/06\\\/15\\\/nows-interest-in-pharmaceutical-gender-equity-seems-to-have-disappeared-with-its-funding\\\/\"},\"wordCount\":423,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/blogs.bmj.com\\\/medical-ethics\\\/#organization\"},\"keywords\":[\"Public Health\",\"Research\"],\"articleSection\":[\"Blogosphere\",\"Conferences\",\"Regulation and Regulators\",\"Research Ethics\",\"WTF?\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/blogs.bmj.com\\\/medical-ethics\\\/2017\\\/06\\\/15\\\/nows-interest-in-pharmaceutical-gender-equity-seems-to-have-disappeared-with-its-funding\\\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/blogs.bmj.com\\\/medical-ethics\\\/2017\\\/06\\\/15\\\/nows-interest-in-pharmaceutical-gender-equity-seems-to-have-disappeared-with-its-funding\\\/\",\"url\":\"https:\\\/\\\/blogs.bmj.com\\\/medical-ethics\\\/2017\\\/06\\\/15\\\/nows-interest-in-pharmaceutical-gender-equity-seems-to-have-disappeared-with-its-funding\\\/\",\"name\":\"\\\"NOW\u2019s interest in pharmaceutical gender equity seems to have disappeared with its funding.\\\" - Journal of Medical Ethics blog\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/blogs.bmj.com\\\/medical-ethics\\\/#website\"},\"datePublished\":\"2017-06-15T14:12:47+00:00\",\"dateModified\":\"2017-06-15T20:28:00+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/blogs.bmj.com\\\/medical-ethics\\\/2017\\\/06\\\/15\\\/nows-interest-in-pharmaceutical-gender-equity-seems-to-have-disappeared-with-its-funding\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/blogs.bmj.com\\\/medical-ethics\\\/2017\\\/06\\\/15\\\/nows-interest-in-pharmaceutical-gender-equity-seems-to-have-disappeared-with-its-funding\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/blogs.bmj.com\\\/medical-ethics\\\/2017\\\/06\\\/15\\\/nows-interest-in-pharmaceutical-gender-equity-seems-to-have-disappeared-with-its-funding\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/blogs.bmj.com\\\/medical-ethics\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"&#8220;NOW\u2019s interest in pharmaceutical gender equity seems to have disappeared with its funding.&#8221;\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/blogs.bmj.com\\\/medical-ethics\\\/#website\",\"url\":\"https:\\\/\\\/blogs.bmj.com\\\/medical-ethics\\\/\",\"name\":\"Journal of Medical Ethics blog\",\"description\":\"A blog to discuss the ethics of medicine in its many guises and formats.\",\"publisher\":{\"@id\":\"https:\\\/\\\/blogs.bmj.com\\\/medical-ethics\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/blogs.bmj.com\\\/medical-ethics\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/blogs.bmj.com\\\/medical-ethics\\\/#organization\",\"name\":\"Journal of Medical Ethics blog\",\"url\":\"https:\\\/\\\/blogs.bmj.com\\\/medical-ethics\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/blogs.bmj.com\\\/medical-ethics\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/blogs.bmj.com\\\/medical-ethics\\\/files\\\/2026\\\/04\\\/jme-logo.png\",\"contentUrl\":\"https:\\\/\\\/blogs.bmj.com\\\/medical-ethics\\\/files\\\/2026\\\/04\\\/jme-logo.png\",\"width\":200,\"height\":50,\"caption\":\"Journal of Medical Ethics blog\"},\"image\":{\"@id\":\"https:\\\/\\\/blogs.bmj.com\\\/medical-ethics\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/blogs.bmj.com\\\/medical-ethics\\\/#\\\/schema\\\/person\\\/ba3da426ed20e8f1d933ca367d8216fe\",\"name\":\"BMJ\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/b4d8f39281bcae118348a1c027347b8e53b82d42520e774a8b50dd9a6ac6c01d?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/b4d8f39281bcae118348a1c027347b8e53b82d42520e774a8b50dd9a6ac6c01d?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/b4d8f39281bcae118348a1c027347b8e53b82d42520e774a8b50dd9a6ac6c01d?s=96&d=mm&r=g\",\"caption\":\"BMJ\"},\"sameAs\":[\"https:\\\/\\\/blogs.bmj.com\\\/\"],\"url\":\"https:\\\/\\\/blogs.bmj.com\\\/medical-ethics\\\/author\\\/admin\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"\"NOW\u2019s interest in pharmaceutical gender equity seems to have disappeared with its funding.\" - Journal of Medical Ethics blog","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/blogs.bmj.com\/medical-ethics\/2017\/06\/15\/nows-interest-in-pharmaceutical-gender-equity-seems-to-have-disappeared-with-its-funding\/","og_locale":"en_US","og_type":"article","og_title":"\"NOW\u2019s interest in pharmaceutical gender equity seems to have disappeared with its funding.\" - Journal of Medical Ethics blog","og_description":"There&#8217;s a remarkable piece on the Hastings Center&#8217;s blog by Alycia Hogenmiller about a drug called Addyi. \u00a0Addyi is a drug that doesn&#8217;t work to treat a condition that doesn&#8217;t exist, pushed by campaigners who are actually industry shills. Sprout Pharmaceuticals, run by Cindy and Robert Whitehead, was determined to obtain regulatory approval for flibanserin [...]Read More...","og_url":"https:\/\/blogs.bmj.com\/medical-ethics\/2017\/06\/15\/nows-interest-in-pharmaceutical-gender-equity-seems-to-have-disappeared-with-its-funding\/","og_site_name":"Journal of Medical Ethics blog","article_published_time":"2017-06-15T14:12:47+00:00","article_modified_time":"2017-06-15T20:28:00+00:00","author":"BMJ","twitter_card":"summary_large_image","twitter_misc":{"Written by":"BMJ","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/blogs.bmj.com\/medical-ethics\/2017\/06\/15\/nows-interest-in-pharmaceutical-gender-equity-seems-to-have-disappeared-with-its-funding\/#article","isPartOf":{"@id":"https:\/\/blogs.bmj.com\/medical-ethics\/2017\/06\/15\/nows-interest-in-pharmaceutical-gender-equity-seems-to-have-disappeared-with-its-funding\/"},"author":{"name":"BMJ","@id":"https:\/\/blogs.bmj.com\/medical-ethics\/#\/schema\/person\/ba3da426ed20e8f1d933ca367d8216fe"},"headline":"&#8220;NOW\u2019s interest in pharmaceutical gender equity seems to have disappeared with its funding.&#8221;","datePublished":"2017-06-15T14:12:47+00:00","dateModified":"2017-06-15T20:28:00+00:00","mainEntityOfPage":{"@id":"https:\/\/blogs.bmj.com\/medical-ethics\/2017\/06\/15\/nows-interest-in-pharmaceutical-gender-equity-seems-to-have-disappeared-with-its-funding\/"},"wordCount":423,"commentCount":0,"publisher":{"@id":"https:\/\/blogs.bmj.com\/medical-ethics\/#organization"},"keywords":["Public Health","Research"],"articleSection":["Blogosphere","Conferences","Regulation and Regulators","Research Ethics","WTF?"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/blogs.bmj.com\/medical-ethics\/2017\/06\/15\/nows-interest-in-pharmaceutical-gender-equity-seems-to-have-disappeared-with-its-funding\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/blogs.bmj.com\/medical-ethics\/2017\/06\/15\/nows-interest-in-pharmaceutical-gender-equity-seems-to-have-disappeared-with-its-funding\/","url":"https:\/\/blogs.bmj.com\/medical-ethics\/2017\/06\/15\/nows-interest-in-pharmaceutical-gender-equity-seems-to-have-disappeared-with-its-funding\/","name":"\"NOW\u2019s interest in pharmaceutical gender equity seems to have disappeared with its funding.\" - Journal of Medical Ethics blog","isPartOf":{"@id":"https:\/\/blogs.bmj.com\/medical-ethics\/#website"},"datePublished":"2017-06-15T14:12:47+00:00","dateModified":"2017-06-15T20:28:00+00:00","breadcrumb":{"@id":"https:\/\/blogs.bmj.com\/medical-ethics\/2017\/06\/15\/nows-interest-in-pharmaceutical-gender-equity-seems-to-have-disappeared-with-its-funding\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/blogs.bmj.com\/medical-ethics\/2017\/06\/15\/nows-interest-in-pharmaceutical-gender-equity-seems-to-have-disappeared-with-its-funding\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/blogs.bmj.com\/medical-ethics\/2017\/06\/15\/nows-interest-in-pharmaceutical-gender-equity-seems-to-have-disappeared-with-its-funding\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/blogs.bmj.com\/medical-ethics\/"},{"@type":"ListItem","position":2,"name":"&#8220;NOW\u2019s interest in pharmaceutical gender equity seems to have disappeared with its funding.&#8221;"}]},{"@type":"WebSite","@id":"https:\/\/blogs.bmj.com\/medical-ethics\/#website","url":"https:\/\/blogs.bmj.com\/medical-ethics\/","name":"Journal of Medical Ethics blog","description":"A blog to discuss the ethics of medicine in its many guises and formats.","publisher":{"@id":"https:\/\/blogs.bmj.com\/medical-ethics\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/blogs.bmj.com\/medical-ethics\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/blogs.bmj.com\/medical-ethics\/#organization","name":"Journal of Medical Ethics blog","url":"https:\/\/blogs.bmj.com\/medical-ethics\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/blogs.bmj.com\/medical-ethics\/#\/schema\/logo\/image\/","url":"https:\/\/blogs.bmj.com\/medical-ethics\/files\/2026\/04\/jme-logo.png","contentUrl":"https:\/\/blogs.bmj.com\/medical-ethics\/files\/2026\/04\/jme-logo.png","width":200,"height":50,"caption":"Journal of Medical Ethics blog"},"image":{"@id":"https:\/\/blogs.bmj.com\/medical-ethics\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/blogs.bmj.com\/medical-ethics\/#\/schema\/person\/ba3da426ed20e8f1d933ca367d8216fe","name":"BMJ","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/b4d8f39281bcae118348a1c027347b8e53b82d42520e774a8b50dd9a6ac6c01d?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/b4d8f39281bcae118348a1c027347b8e53b82d42520e774a8b50dd9a6ac6c01d?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/b4d8f39281bcae118348a1c027347b8e53b82d42520e774a8b50dd9a6ac6c01d?s=96&d=mm&r=g","caption":"BMJ"},"sameAs":["https:\/\/blogs.bmj.com\/"],"url":"https:\/\/blogs.bmj.com\/medical-ethics\/author\/admin\/"}]}},"_links":{"self":[{"href":"https:\/\/blogs.bmj.com\/medical-ethics\/wp-json\/wp\/v2\/posts\/3179","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/blogs.bmj.com\/medical-ethics\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/blogs.bmj.com\/medical-ethics\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/blogs.bmj.com\/medical-ethics\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/blogs.bmj.com\/medical-ethics\/wp-json\/wp\/v2\/comments?post=3179"}],"version-history":[{"count":0,"href":"https:\/\/blogs.bmj.com\/medical-ethics\/wp-json\/wp\/v2\/posts\/3179\/revisions"}],"wp:attachment":[{"href":"https:\/\/blogs.bmj.com\/medical-ethics\/wp-json\/wp\/v2\/media?parent=3179"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/blogs.bmj.com\/medical-ethics\/wp-json\/wp\/v2\/categories?post=3179"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/blogs.bmj.com\/medical-ethics\/wp-json\/wp\/v2\/tags?post=3179"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}